* HOOKIPA Pharma Inc HOOK.OQ HOOK.O is expected to show
a rise
in quarterly revenue when it reports results on August 8
(estimated) for the period ending June 30 2024
* The New York City-based company is expected to report a
164.7% increase in revenue to $7.091 million from $2.68 million
a year ago, according to the mean estimate from 4 analysts,
based on LSEG data.
* LSEG's mean analyst estimate for HOOKIPA Pharma Inc is
for a
loss of $1.25 per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for HOOKIPA
Pharma
Inc is $45.00, above its last closing price of $4.67.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Jan. 1 0001 -1.07 -1.02 1.10 Beat 207.3
Jan. 1 0001 -1.96 -1.93 -2.20 Missed -14
Sep. 30 2023 -2.31 -2.10 -1.70 Beat 19
Jun. 30 2023 -1.86 -2.09 -2.20 Missed -5.3
Jan. -2.23 -2.26 -2.70 Missed -19.5
1 0001
Jan. 1 0001 -1.78 -2.15 -1.70 Beat 20.9
Jan. 1 0001 -2.87 -2.82 -2.50 Beat 11.2
Jun. 30 2022 -3.58 -3.60 -2.30 Beat 36.1
This summary was machine generated August 6 at 15:24 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)